latest news releases from the newsroom
Meet Active Biotech at BIO2003 Annual Convention, June 22-25 in Washington D.C
STOCKHOLM, Sweden, June 18, 2003 (PRIMEZONE) -- Active Biotech (Other OTC:ACTBF) today published new data about the development of its SAIK-MS substance for is a Swedish biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline projects in the areas of autoimmune/inflammatory diseases and cancer. The company's pharmaceutical development is based on an in-depth knowledge in immunology.
Medivir Divests CCS to Segulah
HUDDINGE, Sweden, June 18, 2003 (PRIMEZONE) -- Medivir and Segulah II L.P. announce the signing of a transfer agreement implying Segulah II L.P. acquiring Medivir subsidiary CCS, Clean Chemical Sweden AB and subsidiaries (CCS, Clean Care Sweden (U.K.) Ltd. and Nordic Care Sweden AB).
MTG: Acquisition of Remaining Shares in SDI Media Hong Kong
STOCKHOLM, Sweden, June 18, 2003 (PRIMEZONE) -- Modern Times Group MTG AB (Nasdaq:MTGNY), the international media group, today announced that its SDI Media AB subsidiary has acquired the remaining 40 per cent of the SDI Media operation in Hong Kong. MTG owns 100 per cent of the company, which is the leading subtitling and dubbing company in Asia.
Skanska Sold Entire Shareholding in Nobia
STOCKHOLM, Sweden, June 18, 2003 (PRIMEZONE) -- Skanska AB today sold all of its shares in Nobia AB. A total of 7,203,549 shares, corresponding to 12.5 percent of the number of shares and votes in Nobia, were sold.
CeNeS Pharmaceuticals Plc
CeNeS Announces Termination of its Joint Venture with Elan
CAMBRIDGE, United Kingdom, June 18, 2003 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced that it has reached agreement with Elan Corporation plc (NYSE:ELN) to terminate the CeNeS/Elan joint venture, which was established in June 2001 to develop M6G (morphine-6-glucuronide) for the treatment of pain. CeNeS alone will now plan to take forward and fund the clinical development of M6G as it enters its phase III program for the treatment of post-operative pain.
Hennigan, Bennett and Dorman, LLP
Hennigan, Bennett and Dorman Releases Open Letter to Unsecured Creditors of Peregrine Systems, Inc.
LOS ANGELES, June 17, 2003 (PRIMEZONE) -- The law firm of Hennigan, Bennett and Dorman, representing the Official Committee of Unsecured Creditors (the "Committee") of Peregrine Systems, Inc. (OTC:PRGNQ) and Peregrine Remedy, Inc. (together, "Peregrine") is sending a letter
to unsecured creditors of Peregrine, unanimously urging them to
vote to REJECT the Fourth Amended Plan of Reorganization filed
by Peregrine. A copy of that letter, which describes the reasons
for the Committee's decision to recommend rejection of the
Plan is included below.